Molecular Oncology · 2015 · 125 citations · 80 references
MedicineBioinformaticsOncologyCancer GeneticsMolecular OncologyTranslational OncologyCancer BiomarkersCancer GenomicsChemotherapy ResistanceMalignant NeoplasmsMolecular Tumor ProfilingTherapeutic ResistanceBreast Cancer GenomicsBreast Cancer Resistance MechanismsDrug Resistance BiomarkersDrug Resistance TranscriptomicsPrecision Oncology GenomicsTherapeutic Resistance GenomicsTherapeutic Resistance MechanismsTumor Pharmacogenomic Profiling
Increasingly, the effectiveness of adjuvant chemotherapy agents for breast cancer has been related to changes in the genomic profile of tumors. We investigated correspondence between growth inhibitory concentrations of paclitaxel and gemcitabine (GI50) and gene copy number, mutation, and expression first in breast cancer cell lines and then in patients. Genes encoding direct targets of these drugs, metabolizing enzymes, transporters, and those previously associated with chemoresistance to paclitaxel (n = 31 genes) or gemcitabine (n = 18) were analyzed. A multi-factorial, principal component analysis (MFA) indicated expression was the strongest indicator of sensitivity for paclitaxel, and copy number and expression were informative for gemcitabine. The factors were combined using support vector machines (SVM). Expression of 15 genes (ABCC10, BCL2, BCL2L1, BIRC5, BMF, FGF2, FN1, MAP4, MAPT, NFKB2, SLCO1B3, TLR6, TMEM243, TWIST1, and CSAG2) predicted cell line sensitivity to paclitaxel with 82% accuracy. Copy number profiles of 3 genes (ABCC10, NT5C, TYMS) together with expression of 7 genes (ABCB1, ABCC10, CMPK1, DCTD, NME1, RRM1, RRM2B), predicted gemcitabine response with 85% accuracy. Expression and copy number studies of two independent sets of patients with known responses were then analyzed with these models. These included tumor blocks from 21 patients that were treated with both paclitaxel and gemcitabine, and 319 patients on paclitaxel and anthracycline therapy. A new paclitaxel SVM was derived from an 11-gene subset since data for 4 of the original genes was unavailable. The accuracy of this SVM was similar in cell lines and tumor blocks (70-71%). The gemcitabine SVM exhibited 62% prediction accuracy for the tumor blocks due to the presence of samples with poor nucleic acid integrity. Nevertheless, the paclitaxel SVM predicted sensitivity in 84% of patients with no or minimal residual disease.
80
Comprehensive molecular portraits of human breast tumours
Gene expression profiling predicts clinical outcome of breast cancer
Laura van ‘t Veer, Hongyue Dai, Marc J. van de Vijver et al. · Nature · 2002 · 9.6K citations · Full text
SIFT: predicting amino acid changes that affect protein function
P.C. Ng · Nucleic Acids Research · 2003 · 6.9K citations · Full text
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve, Koei Chin, Jane Fridlyand et al. · Cancer Cell · 2006 · 3.2K citations · Full text
Medicine, Cell Biology, Oncology +14